Effects of 8-bromo-7-methoxychrysin and sorafenib on apoptosis of liver cancer stem-like cells

doi:10.3969/j.issn.2095-4344.2015.45.009

Abstract

Abstract:

BACKGROUND: We tried to combine 8-bromo-7-methoxychrysin and sorafenib in order to offset the tolerance of hepatocellular cancer stem cells to sorafenib, thereby comprehensively improving the therapeutic efficacy on hepatocellular carcinoma.
OBJECTIVE: To observe the effects of 8-bromo-7-methoxychrysin, sorafenib and their combination on apoptosis of liver cancer stem-like cells SMMC-7721, and to analyze their mechanisms.
METHODS: SMMC-7721 cells were treated with 8-bromo-7-methoxychrysin, sorafenib alone and their combination for 24 hours. Then, flow cytometry was used to detect cell apoptosis and western blot assay was used to determine nuclear factor-κB protein expression.
RESULTS AND CONCLUSION: Compared with 8-bromo-7-methoxychrysin group and sorafenib group, the apoptotic rates of SMMC-7721 cells were significantly enhanced after treatment with the combination of 8-bromo-7-methoxychrysin group and sorafenib (2.5, 5, 10, 50 μmol/L), and meanwhile, the protein expression of nuclear factor-κB was down-regulated significantly. These findings indicate that the combined therapy of 8-bromo-7-methoxychrysin group and sorafenib can enhance the apoptosis of SMMC-7721 cells, which may beassociated with down-regulation of nuclear factor-κB protein.
中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Carcinoma, Hepatocellular, Apoptosis, Cell Line, Tumor, NF-kappa B, Tissue Engineering

Aoduntuoya, Zhao Hai-zhen, Liu Rui-jun. Effects of 8-bromo-7-methoxychrysin and sorafenib on apoptosis of liver cancer stem-like cells[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(45): 7263-7267.

Figures/Tables 4

References

[1] Cholongitas E, Burra P. Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant. Transpl Int. 2015;28(4): 503-504.

[2] Snow WM, Stoesz BM, Kelly DM, et al. Roles for NF-κB and gene targets of NF-κB in synaptic plasticity, memory, and navigation. Mol Neurobiol. 2014;49(2):757-770.

[3] 徐成坤,阳波,曹建国.白杨素诱导肝癌Hep3B细胞凋亡机制研究[J]. 医药导报,2014, 33(3):295-298.

[4] Ren KQ, Cao XZ, Liu ZH, et al. 8-bromo-5-hydroxy- 7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling. Int J Oncol. 2013;43(5):1719-1729.

[5] Quan MF, Xiao LH, Liu ZH, et al. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol. 2013; 19(43):7680-7695.

[6] Fernando J, Malfettone A, Cepeda EB, et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer. 2015;136(4):E161-172.

[7] Nishida N, Kitano M, Sakurai T, et al. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. Dig Dis. 2015;33(6):771-779.

[8] Martin del Campo SE, Levine KM, Mundy-Bosse BL, et al. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. J Immunol. 2015; 195(5):1995-2005.

[9] Cao G, Li X, Qin C, et al. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015;21:3144-3151.

[10] Dirscherl K, Karlstetter M, Ebert S, et al. Correction: Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotectivephenotype. J Neuroinflammation. 2012;9(1):72-79.

[11] Ren KQ, Cao XZ, Liu ZH, et al. 8-bromo-5-hydroxy-7- methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.Int J Oncol. 2013;43(5):1719-1729.

[12] Yang XH, Zheng X, Cao JG, et al. 8-Bromo-7-methoxychrysin- induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J Gastroenterol. 2010;16(27): 3385-3393.

[13] 孙建聪,牛道立,夏建川.肝癌干细胞的分离鉴定及耐药性研究[J].实用医学杂志,2014,30(19):3059-3061.

[14] Hamstra DA. Oncology scan--intermittent androgen deprivation and the randomized evidence. Int J Radiat Oncol Biol Phys. 2013;87(3):446-448.

[15] Zhou J, Chen L, Zhang Y, et al. Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721. J Mol Histol. 2014; 45(2):205-216.

[16] 吴戈,肖蕾,艾尼瓦尔•艾木都拉,等.放射性肝纤维化的实验研究中TNF-α、NF-κB p65和TGF-β1动态变化及表达意义[J].中华放射肿瘤学杂志,2014,23(5):390-391.

[17] Gao F, Yang Y, Wang Z, et al. BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation. Cell Immunol. 2015;294(1):1-8.

[18] Li W, Huang H, Niu X, et al. Tetrahydrocoptisine protects rats from LPS-induced acute lung injury. Inflammation. 2014;37(6): 2106-2115.

[19] 朱斌,潘韶英,赵红,等.弥漫性大B细胞淋巴瘤组织中NF-κB p65、P-gp、CYP3A4表达变化及意义[J].山东医药,2014, 54(28): 68-70.

[20] Wei N, Zhang C, He H, et al. Protective effect of saponins extract from Panax japonicus on myocardial infarction: involvement of NF-κB, Sirt1 and mitogen-activated protein kinase signalling pathways and inhibition of inflammation. J Pharm Pharmacol. 2014;66(11):1641-1651.

[21] 吴昶皓,张红卫.索拉非尼诱导肝癌耐药细胞株的建立及功能研究[J].中华实验外科杂志,2014,31(4):757-759.

[22] Baron Toaldo M, Salvatore V, Marinelli S, et al. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Mol Imaging Biol. 2015;17(1): 29-37.

[23] 王琦,王丽佳,刘响,等.CT灌注早期预测索拉非尼对大鼠肝癌的疗效[J].临床放射学杂志,2014,33(11):1773-1777.

[24] Baxter JD, Dunn D, White E, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16 Suppl 1:77-87.

[25] Jariwala N, Rajasekaran D, Srivastava J, et al. Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review). Int J Oncol. 2015;46(2):465-473.